RxDoctor Payments DataLook up a doctor →

Mark Smith, MD

Nephrology · Anchorage, AKNPI 1861479651

Payments from drug & device makers

$610,339in general payments, 2019–2025

Across 528 payments — averaging $1155.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$470K
  • Novo Nordisk AS$49K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$31K
  • Otsuka America Pharmaceutical, Inc.$30K
  • Akebia Therapeutics Inc$16K
  • Vifor Pharma, Inc.$10K
  • plus $5K from 24 others
$7,465in research payments, 2019–2025

Across 10 payments — averaging $746.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$7K

What the payments were for

  • Consulting fees$33,80222%
  • Speaking & faculty fees$99,82766%
  • Travel & lodging$8,9266%
  • Food & beverage$7,5985%
  • Education$2340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nephrology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$153,306
Medicare patients
514
Services billed
2,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone189$182,756
FarxigaDapagliflozin Propanediol139$129,497
VeltassaPatiromer Calcium Sorbitex88$108,615
JardianceEmpagliflozin63$52,144
Cinacalcet Hcl23$14,327
LokelmaSodium Zirconium Cyclosilicate15$9,189
Eplerenone81$7,132
Sevelamer Carbonate92$6,366
Mycophenolate Mofetil11$4,537
Telmisartan110$3,559
Colchicine13$3,456
Losartan Potassium146$1,896
Spironolactone231$1,802
Potassium Citrate ErPotassium Citrate14$1,569
Valsartan28$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$469,969$182,756189 claims
AstraZenecaFarxiga, Lokelma$695$138,687154 claims
Boehringer IngelheimJardiance$71$52,14463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other nephrology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →